Log in

Seelos Therapeutics Stock Forecast, Price & News

+0.03 (+4.05 %)
(As of 10/29/2020 12:00 AM ET)
Today's Range
Now: $0.77
50-Day Range
MA: $0.79
52-Week Range
Now: $0.77
Volume256,619 shs
Average Volume1.23 million shs
Market Capitalization$34.19 million
P/E RatioN/A
Dividend YieldN/A
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of suicidality in post-traumatic stress disorder and in depressive disorder; SLS-005, a protein stabilizer for the treatment of Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for monotherapy in early stage Parkinson's disease patients. Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with Parkinson's disease or Lewy Body Dementia; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and orphan indications; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. The company was founded in 2016 and is headquartered in New York, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.26 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SEEL



Sales & Book Value

Annual Sales$380,000.00


Net Income$-51,260,000.00


Market Cap$34.19 million
Next Earnings Date11/5/2020 (Estimated)
OptionableNot Optionable
+0.03 (+4.05 %)
(As of 10/29/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SEEL News and Ratings via Email

Sign-up to receive the latest news and ratings for SEEL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Seelos Therapeutics (NASDAQ:SEEL) Frequently Asked Questions

How has Seelos Therapeutics' stock price been impacted by COVID-19?

Seelos Therapeutics' stock was trading at $0.78 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SEEL stock has decreased by 1.3% and is now trading at $0.7699.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Seelos Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seelos Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Seelos Therapeutics

When is Seelos Therapeutics' next earnings date?

Seelos Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Seelos Therapeutics

How were Seelos Therapeutics' earnings last quarter?

Seelos Therapeutics, Inc. (NASDAQ:SEEL) announced its quarterly earnings results on Friday, August, 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03.
View Seelos Therapeutics' earnings history

What price target have analysts set for SEEL?

3 brokers have issued twelve-month price targets for Seelos Therapeutics' shares. Their forecasts range from $4.00 to $12.00. On average, they expect Seelos Therapeutics' stock price to reach $6.67 in the next twelve months. This suggests a possible upside of 765.9% from the stock's current price.
View analysts' price targets for Seelos Therapeutics

Are investors shorting Seelos Therapeutics?

Seelos Therapeutics saw a increase in short interest during the month of September. As of September 30th, there was short interest totaling 352,200 shares, an increase of 29.8% from the September 15th total of 271,400 shares. Based on an average trading volume of 1,560,000 shares, the days-to-cover ratio is presently 0.2 days.
View Seelos Therapeutics' Short Interest

Who are some of Seelos Therapeutics' key competitors?

What other stocks do shareholders of Seelos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seelos Therapeutics investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Biocept (BIOC), Onconova Therapeutics (ONTX), Co-Diagnostics (CODX), Heat Biologics (HTBX), Ibio (IBIO) and Opko Health (OPK).

Who are Seelos Therapeutics' key executives?

Seelos Therapeutics' management team includes the following people:
  • Dr. Raj Mehra Ph.D., Founder, Chairman, CEO, Pres & Interim CFO (Age 60, Pay $708.81k)
  • Anthony Marciano, Head of Corp. Communications
  • Gopal Krishna, Head of Manufacturing & Technical Operations
  • Tim Whitaker, Head of R&D
  • Jessica Kardish, Head of Clinical Operations

What is Seelos Therapeutics' stock symbol?

Seelos Therapeutics trades on the NASDAQ under the ticker symbol "SEEL."

How do I buy shares of Seelos Therapeutics?

Shares of SEEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Seelos Therapeutics' stock price today?

One share of SEEL stock can currently be purchased for approximately $0.77.

How big of a company is Seelos Therapeutics?

Seelos Therapeutics has a market capitalization of $34.19 million and generates $380,000.00 in revenue each year. Seelos Therapeutics employs 8 workers across the globe.

What is Seelos Therapeutics' official website?

The official website for Seelos Therapeutics is www.seelostherapeutics.com.

How can I contact Seelos Therapeutics?

Seelos Therapeutics' mailing address is 300 PARK AVENUE 12TH FLOOR, NEW YORK NY, 10022. The company can be reached via phone at 646-293-2100 or via email at [email protected]

This page was last updated on 10/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.